- Phase 3 HDV D-LIVR (Lonafarnib) 75% Enrolled; Full Enrollment Planned in 2021 - Phase 3 HDV LIMT-2 (Lambda) to Initiate in 2021 - Phase 3 COVID-19 TOGETHER Platform Study to Include Lambda Arm - $3.6M U.S. Zokinvy® Net Sales in Q1 2021 PALO ALTO, Calif.

- Lambda arm to enroll up to 800 high-risk, non-hospitalized patients - Primary endpoint is reduction of emergency room visits and hospitalizations PALO ALTO, Calif. , May 3, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on

- Live Conference Call and Webcast at 4:30 PM ET PALO ALTO, Calif. , April 29, 2021 /PRNewswire/ --  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare